Literature DB >> 15854050

An action spectrum for the production of cis-urocanic acid in human skin in vivo.

Pauline McLoone1, Eniko Simics, Alan Barton, Mary Norval, Neil K Gibbs.   

Abstract

Urocanic acid (UCA) is present at millimolar concentrations in mammalian epidermis and undergoes photoisomerization from the naturally occurring trans-isomer to the cis-isomer on exposure to ultraviolet radiation (UVR). Cis-UCA causes downregulation of various immune responses in mouse and human experimental models and has been proposed as both a chromophore and a mediator of UV-induced immune suppression. In this study, the wavelength dependence from 260-340 nm for trans to cis-UCA photoisomerization in human skin was analyzed in five healthy volunteers. The resulting action spectrum demonstrated maximal cis-UCA production in the UVB spectral region of 280-310 nm. This spectral peak is red-shifted to longer wavelengths compared with the erythemal action spectrum. The cis-UCA action spectrum can be used to predict the ability of sunscreens to protect against UVR-induced cis-UCA formation and may assist in explaining discrepancies between sunscreens' abilities to protect against erythema and photoimmunosuppression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15854050     DOI: 10.1111/j.0022-202X.2005.23731.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Re-appraisal of current theories for the development and loss of epidermal pigmentation in hominins and modern humans.

Authors:  Peter M Elias; Mary L Williams
Journal:  J Hum Evol       Date:  2013-03-09       Impact factor: 3.895

2.  An action spectrum (290-320 nm) for TNFalpha protein in human skin in vivo suggests that basal-layer epidermal DNA is the chromophore.

Authors:  Susan L Walker; Antony R Young
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-19       Impact factor: 11.205

3.  Suppression of an established immune response by UVA--a critical role for mast cells.

Authors:  Stephen E Ullrich; Dat X Nghiem; Polina Khaskina
Journal:  Photochem Photobiol       Date:  2007 Sep-Oct       Impact factor: 3.421

4.  Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome.

Authors:  Gábor Mócsai; Krisztián Gáspár; Zsolt Dajnoki; Beáta Tóth; Edit Gyimesi; Tamás Bíró; László Maródi; Andrea Szegedi
Journal:  J Clin Immunol       Date:  2015-10-09       Impact factor: 8.317

Review 5.  One remarkable molecule: filaggrin.

Authors:  Sara J Brown; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

6.  Filaggrin gene mutation c.3321delA is associated with various clinical features of atopic dermatitis in the Chinese Han population.

Authors:  Li Meng; Li Wang; Huayang Tang; Xianfa Tang; Xiaoyun Jiang; Jinhua Zhao; Jing Gao; Bing Li; Xuhui Fu; Yan Chen; Weiyi Yao; Wenying Zhan; Bo Wu; Dawei Duan; Changbing Shen; Hui Cheng; Xianbo Zuo; Sen Yang; Liangdan Sun; Xuejun Zhang
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

7.  Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children.

Authors:  S J Brown; C L Relton; H Liao; Y Zhao; A Sandilands; W H I McLean; H J Cordell; N J Reynolds
Journal:  Br J Dermatol       Date:  2009-06-11       Impact factor: 9.302

8.  Filaggrin genotype does not determine the skin's threshold to UV-induced erythema.

Authors:  Deborah Forbes; Leona Johnston; June Gardner; Stephanie F MacCallum; Linda E Campbell; Albena T Dinkova-Kostova; W H Irwin McLean; Sally H Ibbotson; Robert S Dawe; Sara J Brown
Journal:  J Allergy Clin Immunol       Date:  2016-01-29       Impact factor: 10.793

Review 9.  From Early Immunomodulatory Triggers to Immunosuppressive Outcome: Therapeutic Implications of the Complex Interplay Between the Wavebands of Sunlight and the Skin.

Authors:  Pablo A Vieyra-Garcia; Peter Wolf
Journal:  Front Med (Lausanne)       Date:  2018-09-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.